text: COVID 19 cardiac injury Implications for long term surveillance and outcomes in survivors Up to 20 30 of patients hospitalized with coronavirus disease 2019 COVID 19 have evidence of myocardial involvement Acute cardiac injury in patients hospitalized with COVID 19 is associated with higher morbidity and mortality There are no data on how acute treatment of COVID 19 may affect the convalescent phase or long term cardiac recovery and function Myocarditis from other viral pathogens can evolve into overt or subclinical myocardial dysfunction and sudden death has been described in the convalescent phase of viral myocarditis This raises concerns for patients recovering from COVID 19 Some patients will have subclinical and possibly overt cardiovascular abnormalities Patients with ostensibly recovered cardiac function may still be at risk of cardiomyopathy and cardiac arrhythmias Screening for residual cardiac involvement in the convalescent phase for patients recovered from COVID 19 associated cardiac injury is needed The type of testing and therapies for post COVID 19 myocardial dysfunction will need to be determined Therefore now is the time to plan for appropriate registries and clinical trials to properly assess these issues and prepare for long term sequelae of post COVID 19 cardiac syndrome 